Haemonetics (HAE) Tops Q3 EPS by 2c

Haemonetics (NYSE: HAE) reported Q3 EPS of $0.48, $0.02 better than the analyst estimate of $0.46. Revenue for the quarter came in at $233.4 million versus the consensus estimate of $237.37 million.

Haemonetics reaffirmed FY2016 guidance.

For earnings history and earnings-related data on Haemonetics (HAE) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49